原文标题：
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the
United States over the next five years
原文连结：https://tinyurl.com/2h8hnjuv
发布时间：Tue, April 22, 2025 at 1:00 PM GMT+8
记者署名：F. Hoffmann-La Roche Ltd
原文内容：
Basel, 22 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that
it will invest USD 50 billion into the United States of America in the next
five years. These investments further strengthen Roche’s already significant
US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical
and Diagnostics Divisions, and are expected to create more than 12,000 new
jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new
and expanded facilities.
As part of this investment, Roche will increase its existing footprint of more
than 25,000 employees in 24 sites across eight US states. The investment will
include:
Expanded and upgraded US manufacturing and distribution capabilities for its
innovative medicines and diagnostics portfolio in Kentucky, Indiana, New
Jersey, Oregon and California
A state-of-the-art gene therapy manufacturing facility in Pennsylvania
A new 900,000 square foot manufacturing centre to support Roche’s expanding
portfolio of next generation weight loss medicines (location to be announced)
A new manufacturing facility for continuous glucose monitoring in Indiana
A new R&D centre in Massachusetts, conducting cutting-edge artificial
intelligence (AI) research and serving as hub for our new cardiovascular,
renal and metabolism research and development efforts
Significant expansion and upgrading of our existing pharmaceuticals and
diagnostics R&D centres in Arizona, Indiana and California
“Roche is a Swiss company with a strong heritage in more than 130 countries
globally. Today’s announced investments underscore our long-standing
commitment to research, development and manufacturing in the US,” said Thomas
Schinecker, Roche Group CEO. “We are proud of our 110 year legacy in the
United States which has been a key driver for jobs, innovation and the
creation of intellectual property in the US, across both our Pharmaceutical
and Diagnostics Divisions. Our investments of USD 50 billion over the next
five years will lay the foundation for our next era of innovation and growth,
benefiting patients in the US and around the world.”
Once all new and expanded manufacturing capacity comes on-line, Roche will
export more medicines from the US than it imports. Today, its diagnostics
division already has an export surplus from the US to other countries.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial
manufacturers of branded medicines, Roche has grown into the world’s largest
biotechnology company and the global leader in in-vitro diagnostics. The
company pursues scientific excellence to discover and develop medicines and
diagnostics for improving and saving the lives of people around the world. We
are a pioneer in personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide the best
care for each person we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the clinical
practice.
For over 125 years, sustainability has been an integral part of Roche’s
business. As a science-driven company, our greatest contribution to society is
developing innovative medicines and diagnostics that help people live
healthier lives. Roche is committed to the Science Based Targets initiative
and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
心得/评论：
罗氏（SIX: RO, ROG; OTCQX: RHHBY）今日宣布，将在未来五年内向美国
投资500亿美元。这些投资将进一步巩固罗氏在美国的显著影响力，该公司
目前在美国拥有13个制造基地和15个研发基地，涵盖制药和诊断部门，预
计将创造超过12,000个新就业机会，包括近6,500个建筑工作岗位，以及新
扩建设施中的1,000个工作岗位。
作为此次投资的一部分，罗氏将扩大其在美国八个州24个地点、超过25,000
名员工的现有规模。
投资内容包括：
在肯塔基州、印第安纳州、新泽西州、俄勒冈州和加利福尼亚州扩展和升级
其创新药物和诊断产品组合的制造和分销能力
在宾夕法尼亚州建立一座先进的基因疗法制造设施
建立一个90万平方英尺的新制造中心，以支持罗氏不断扩展的下一代减重药
物产品组合（地点待公布）
在印第安纳州建立一座用于连续血糖监测的新制造设施
在马萨诸塞州建立一个新的研发中心，进行尖端人工智能（AI）研究，并作
为心血管、肾脏和代谢研究与开发的新中心
在亚利桑那州、印第安纳州和加利福尼亚州显著扩展和升级现有的制药和诊
断研发中心
罗氏集团首席执行官托马斯·辛内克（Thomas Schinecker）表示：“罗氏是
一家瑞士公司，在全球130多个国家拥有悠久历史。今天宣布的投资凸显了我
们对美国研发和制造的长期承诺。我们为在美国110年的传承感到自豪，这一
直是美国就业、创新和知识产权创造的关键驱动力，涵盖我们的制药和诊断
部门。未来五年500亿美元的投资将为我们的下一阶段创新和增长奠定基础，
造福美国及全球的患者。”
一旦所有新建和扩建的制造能力上线，罗氏从美国出口的药物将超过其进口量
。目前，其诊断部门已从美国向其他国家实现出口顺差。
***
丸子
川普一定又要臭弹了
他又要说他的关税政策又成功了
又一家跨国先进的大公司要到美国投资了